TrialCurvePreoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: reconstructed Kaplan–Meier curves
Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Cancer Commun (Lond). 2026 Jan 27;46:0006. doi: 10.34133/cancomm.0006 |
|---|---|
| DOI | 10.34133/cancomm.0006 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Disease-free survival — Modified intention-to-treat cohort
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pre-CT 49.0 months; Pre-CRT 38.0 months. Survival at 18 months: Pre-CT 72%; Pre-CRT 66%. Hazard ratio Pre-CRT vs Pre-CT 1.03 (95% CI 0.70–1.52).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pre-CT | 94 | 49 | 49.0 |
| Pre-CRT | 100 | 54 | 38.0 |
- Pre-CRT vs Pre-CT: reconstructed HR 1.03 (95% CI 0.70–1.52)
Landmark survival (reconstructed)
| Time | Pre-CT | Pre-CRT |
|---|---|---|
| 6 mo | 89.4% | 94.0% |
| 12 mo | 78.6% | 77.0% |
| 18 mo | 72.1% | 66.0% |
| 24 mo | 61.2% | 58.9% |
| 36 mo | 52.4% | 51.6% |
| 48 mo | 52.4% | 46.2% |
| 60 mo | 48.2% | 44.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.02, reconstructed 1.03 pass
Overall survival — Modified intention-to-treat cohort
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pre-CRT 66.0 months; Pre-CT 67.8 months. Survival at 18 months: Pre-CRT 79%; Pre-CT 83%. Hazard ratio Pre-CRT vs Pre-CT 0.97 (95% CI 0.64–1.48).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pre-CRT | 100 | 44 | 66.0 |
| Pre-CT | 94 | 43 | 67.8 |
- Pre-CRT vs Pre-CT: reconstructed HR 0.97 (95% CI 0.64–1.48)
Landmark survival (reconstructed)
| Time | Pre-CRT | Pre-CT |
|---|---|---|
| 6 mo | 98.0% | 95.7% |
| 12 mo | 92.7% | 90.2% |
| 18 mo | 78.9% | 83.5% |
| 24 mo | 72.5% | 74.5% |
| 36 mo | 63.6% | 59.8% |
| 48 mo | 57.6% | 58.5% |
| 60 mo | 53.0% | 52.1% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.97, reconstructed 0.97 pass
Disease-free survival — R0 resection cohort
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pre-CT not reached; Pre-CRT not reached. Survival at 18 months: Pre-CT 86%; Pre-CRT 81%. Hazard ratio Pre-CRT vs Pre-CT 1.09 (95% CI 0.66–1.81).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pre-CT | 70 | 27 | not reached |
| Pre-CRT | 81 | 33 | not reached |
- Pre-CRT vs Pre-CT: reconstructed HR 1.09 (95% CI 0.66–1.81)
Landmark survival (reconstructed)
| Time | Pre-CT | Pre-CRT |
|---|---|---|
| 6 mo | 98.6% | 100.0% |
| 12 mo | 91.3% | 89.9% |
| 18 mo | 85.5% | 81.0% |
| 24 mo | 75.2% | 73.3% |
| 36 mo | 64.9% | 64.1% |
| 48 mo | 64.9% | 58.5% |
| 60 mo | 61.4% | 56.8% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.1, reconstructed 1.09 pass
Overall survival — R0 resection cohort
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Pre-CT not reached; Pre-CRT not reached. Survival at 18 months: Pre-CT 93%; Pre-CRT 90%. Hazard ratio Pre-CT vs Pre-CRT 0.88 (95% CI 0.52–1.51).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pre-CT | 70 | 24 | not reached |
| Pre-CRT | 81 | 30 | not reached |
- Pre-CT vs Pre-CRT: reconstructed HR 0.88 (95% CI 0.52–1.51)
Landmark survival (reconstructed)
| Time | Pre-CT | Pre-CRT |
|---|---|---|
| 6 mo | 100.0% | 100.0% |
| 12 mo | 97.1% | 98.7% |
| 18 mo | 92.8% | 89.7% |
| 24 mo | 87.0% | 80.8% |
| 36 mo | 73.8% | 71.4% |
| 48 mo | 70.8% | 67.1% |
| 60 mo | 62.8% | 61.7% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.17, reconstructed 1.13 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CheckMate 648: Duration of response (per BICR); Overall survival; Progression-free survival (per BICR)
- Gastrectomy and second-line chemotherapy in advanced gastric cancer: Overall survival; Overall survival (IPTW-adjusted); Progression-free survival; Progression
- Neoadjuvant chemoradiotherapy vs adjuvant therapy in ESCC: Disease-free survival; Overall survival
- Chemoradiotherapy with S-1 in older patients with esophageal cancer: Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials